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Purpose/Objective: The scheme of standard radiotherapy for 
breast cancer treatment involves a high total dose in 25 
fractions. However, a decrease in the total dose, together 
with an increase in the dose per fraction (hypofractionation) 
is discussed to be at least as effective as standard treatment. 
The objective of our study is to analyze the results in local 
control, acute and late toxicity and cosmetic outcome in 
patients treated with hypofractionated radiation therapy 
after conservative surgery for breast cancer in our center. 
Materials and Methods: A retrospective analysis of all women 
diagnosed with breast cancer (Stage 0-III) and treated with 
breast-conserving surgery followed by hypofractionated 
scheme from 2006 to 2011. Total dose on mammary gland: 
42.4 Gy to 2.65 Gy / fraction, for a total of 16 sessions with 
concomitant boost to 7.7 Gy (0.48 Gy / fraction). We 
included patients treated with chemotherapy, hormonal 
therapy and trastuzumab. Acute and late toxicities were 
scored according to the Common Terminology Criteria for 
adverse Events version 4.0 and cosmetic outcome were 
assessed during follow-up every three months up to 2 years 
and every six months up to 5 years after radiotherapy.  
Results: We have treated 143 women with hypofractionated 
scheme. After a median follow up of 36 months, the local 
recurrence rate was 1.4%, only 3.5% experienced nodal 
relapse, one patient developed a contralateral breast cancer 
and 6.3% had distant metastases as first event. There was no 
acute toxicity in 28.4% of cases, being the most frequent 
grade 1 radiodermatitis (61.1%). Regarding late toxicity, this 
was not observed in 65.6%, being grade 1 fibrosis in the 
treated area the most common. The cosmetic outcome was 
good or excellent in 90% of patients treated. At the end of 
the study, 83.8% remained alive without disease, 7% alive 
with disease, 4.9% exitus due to tumor and 4.2% were died 
due to other causes. 
Conclusions: The hipofractionated scheme after conservative 
surgery in breast cancer provides a good control of the 
disease without causing excessive toxicity and providing good 
cosmetic outcomes. Similar results to standard treatment can 
be obtained with a significant reduction in overall treatment 
time. 
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Purpose/Objective: Early breast cancer treated with breast 
conservative therapy (BCT), usually has a good prognosis. 
Recommended target field of RT field is whole breast. 
However, added to the results from MA.20 about regional 
nodal irradiation (RNI) to patients with pN1 status, EORTC 
22922/10925 reported the benefit of RNI for overall survival 
including internal mammary and medial supraclavicular 
lymph node chain especially in tumors situated in medial 
(=inner/central) site without axillary lymph node metastasis. 
Based on our long term date specifically focused on tumor 
site, we assessed the possible utilization of RNI for 
application guideline of breast cancer in Japan. 
Materials and Methods: A total number of patients who were 
treated with BCT are 1200 in our institution. Patients with 
simultaneous bilateral breast cancer and non-invasive breast 
cancer were excluded. Cases with RNI were also excluded. 
1079 cases out of 1200 treated with BCT until December 2012 
were analyzed. 
Median age at diagnosis is 53 years (range: 25-85). Major 
histological type is invasive ductal cancer (93.4%). Tumor 
sizes of origin was in T1; 65.0%, T2; 32.6%, and T3; 1.1%. 
Positive lymph node metastasis was seen in 24.7%. 37.6% of 
patients received chemotherapy, and 73.3% underwent 
hormone therapy. All patients were treated with 
postoperative whole breast RT, in which 37.8% received boost 
RT of 10-14Gy. 
Results: Median follow up period was 120 months (range: 4-
300). A number of tumors located in inner site was 393 
(36.8%), and a number of tumors in outer site was 676 
(63.2%). According to EORTC trial, centrally situated cases 
were regarded as inner cases at the analysis. Ten year overall 
survival rate was favorable (90.1% at inner site and 92.7% at 
outer site (p=0.189)), local recurrence free survival (LRFS) at 
inner/outer site were 90.1%/93.7% (p=0.79), distant 
metastasis free survival (DMFS) were 88.4%/90.1% (p=0.594), 
and disease free survival (DFS) were 72.9%/79.4% (p=0.03) 
respectively. Only DFS was significantly better in outer 
group. 
In cases with positive nodes, LRFS, DMFS, and DFS were not 
significantly different between inner and outer sites. Notably 
in cases with negative nodes, LRFS/DFS/OS of inner situated 
cases were statistically significantly worse. 
Conclusions: In current clinical practice, the whole breast RT 
is recommended to patients with inner situated tumors, 
however, especially in the patients with negative nodes, RNI 
should be considered as a state of the art strategy. 
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Purpose/Objective: Neoadjuvant systemic therapy (NAST) in 
breast cancer potentially down-stages disease, thereby 
posing challenges to the standard indications for nodal 
irradiation. We assessed the pattern of NAST utilization in our 
province and its effect on the recommendation for nodal 
radiotherapy (RT). 
Materials and Methods: Of the 11,628 patients with stages I 
to III breast cancer from 2007-2012, 603 patients (5.2%) were 
treated with NAST. Data from our provincial database were 
obtained to determine relationships between NAST use and 
nodal irradiation. 
